- Home
- VSNT vs LEGN Comparison
VSNT vs LEGN Comparison
Compare VSNT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$30.88
HOLD
Current Price
$19.72
Company Overview
Basic Information| Metric | VSNT | LEGN |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VSNT | LEGN |
|---|---|---|
| Price | $30.88 | $19.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $43.00 | ★ $63.46 |
| AVG Volume (30 Days) | ★ 2.6M | 2.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $67.72 |
| Revenue Next Year | N/A | $43.82 |
| P/E Ratio | $3.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.17 | $16.24 |
| 52 Week High | $35.31 | $45.30 |
Technical Indicators
Market Signals| Indicator | VSNT | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 54.61 |
| Support Level | $27.17 | $16.24 |
| Resistance Level | $30.74 | $23.68 |
| Average True Range (ATR) | 1.07 | 0.91 |
| MACD | 0.20 | 0.45 |
| Stochastic Oscillator | 85.85 | 62.05 |
Price Performance
Historical Comparison VSNT
LEGN
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.